Thank you, Mr. Chair.
I'm certainly glad that this conversation has evolved into a national conversation, because the evidence that we're hearing is that more and more of our veterans and our servicemen and servicewomen have been affected by this.
Brigadier-General MacKay, I'm trying to work out the timeline here. I know in your testimony today you spoke about the decrease in the selection of mefloquine during the last decade. In the early 2000s, mefloquine was the most often used antimalarial. This started changing in the mid-2000s. That would be about 2005, I would assume. Then you also said, in response to a question about why this is happening, that it may be more publicity about this than anything else.
This really didn't start becoming an issue until about 2013 or so, and here we are in 2016. In 2013, the issue of suicide became a little more prevalent. Mr. Dowe brought that to the forefront. We had Mr. Dowe here last week to discuss this. Why did we see such a drastic reduction in the use of mefloquine within the military in that period? It wasn't publicity, I would suggest. I would suggest it was more perhaps that the effects of the drug were starting to be known.
I'm just wondering if you can speak specifically about that reduction.